Program
BLU-808
A development code.
In Sanofi's pipeline, Wild-type KIT inhibitor
. Its studies are mostly in Chronic Urticaria, led by Sanofi.
Furthest: phase 2, since Apr 3, 20253 company-led studies, 1 open or runningNext primary completion: Dec 31, 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 31 open or running | phase 2since Apr 3, 2025 | Apr 3, 2025 | Dec 31, 2026phase 2 · NCT06931405 |
- Named in Sanofi’s own pipeline as
SAR449028
, phase 2, as of Sep 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 3, 2025First studies: 2 phase 2 studiesFirst studyNCT06922448, NCT06931405
- Apr 22, 2025Phase 1 study in Healthy ParticipantsNCT06948032 · 95 enrolled · United States
Ahead
- Dec 31, 2026Primary completion: phase 2 study in Chronic Inducible UrticariaNCT06931405
TargetBeta
“Wild-type KIT inhibitor”the company's pipeline, read by Claude · source
“This is a 2-part, proof-of-concept study to be conducted globally, designed to evaluate the safety, tolerability, clinical activity, pharmacokinetics, and pharmacodynamics of BLU-808, a wild type KIT inhibitor, in participants with CIndU (Part A) or CSU (Part B).”study summary, read by Claude · the study
Other programs on KIT
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| imatinibrule | Novartis | phase 4 | 70 |
| regorafenibrule | Bayer | phase 4 | 40 |
| Avapritinibrule | Sanofi | phase 4 | 10 |
| anlotinibrule | Sino Biopharmaceutical | phase 3 | 40 |
| masitinibrule | AB Science | phase 3 | 38 |
| quizartinibrule | Daiichi Sankyo | phase 3 | 22 |
| ripretinibrule | Ono Pharmaceutical | phase 3 | 9 |
| velzatinib | GlaxoSmithKline | phase 3 | 8 |
| seralutinibrule | gb002-inc-a-wholly-owned-subsidiary-of-gossamer-bio-inc | phase 3 | 8 |
| elenestinib | Sanofi | phase 3 | 3 |
| NB-003rule | ningbo-newbay-technology-development-co-ltd | phase 3 | 2 |
| briquilimabrule | jasper-therapeutics-inc | phase 2 | 7 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06948032Healthy Participants · United States | 1 | Completed | Jan 21, 2025 | 95 |
| NCT06931405Chronic Inducible Urticaria · United States, Denmark, Germany and more | 2 | Active, not recruiting | Dec 31, 2026 | 105 |
| NCT06922448Allergic Rhinoconjunctivitis · Canada | 2 | Completed | Sep 8, 2025 | 21 |
How it is read
Names in the registry
- “BLU-808”, 3 entries
Codes read as this program: BLU808.
Conditions, from the studies’ own filings
- Chronic Urticaria, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.